Kurse werden geladen...
Prognose
Kaufen | 2 |
Halten | 1 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting
Shepherd Center's Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS Shepherd Center's Dr. Deborah Backus to Showcase Final Results of PoNSTEP Study, Providing New Insight into Maximizing Impact of Neuromodulation to Improve Gait in People with MS» Mehr auf globenewswire.com
Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device
United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement United Healthcare approves claim for PoNS Device at out-of-network adjusted list price, becoming the second payer to join Anthem in providing PoNS reimbursement» Mehr auf globenewswire.com
Helius Medical Technologies Announces Reverse Stock Split
NEWTOWN, Pa., April 30, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced today a 1-for-15 reverse split of its Class A common stock, par value $0.001 (“common stock”), effective at 5:00 pm Eastern time on May 1, 2025.» Mehr auf globenewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 45,29k | 63,79% |
Bruttoeinkommen | −66,55k | 698,57% |
Nettoeinkommen | −3,55 Mio | 52,18% |
EBITDA | −3,70 Mio | 17,45% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 1,90 Mio€ |
Anzahl Aktien | 528,06k |
52 Wochen-Hoch/Tief | 21,11€ - 2,84€ |
Dividenden | Nein |
Beta | 1,11 |
KGV (PE Ratio) | −0,16 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 1,61 |
KUV (PS Ratio) | 4,98 |
Unternehmensprofil
Name | Unbekanntes Asset |
CEO | Dane Carl Andreeff |
Mitarbeiter | 21 |
Assets entdecken
Shareholder von Unbekanntes Asset investieren auch in folgende Assets